journal article·2021-03

Patient‐Derived Prostate Cancer Explants: A Clinically Relevant Model to Assess siRNA‐Based Nanomedicines

Terence Tieu, Swati Irani, Kayla L. Bremert, Natalie K. Ryan, Marcin Wojnilowicz, Madison Helm, Helmut Thissen, Nicolas H. Voelcker, Lisa M. Butler, Anna Cifuentes‐Rius

Advanced Healthcare Materials· Volume 10· Issue 6
Publisher page

Abstract

Abstract Over the last thirty years, research in nanomedicine has widely been focused on applications in cancer therapeutics. However, despite the plethora of reported nanoscale drug delivery systems that can successfully eradicate solid tumor xenografts in vivo, many of these formulations have not yet achieved clinical translation. This issue particularly pertains to the delivery of small interfering RNA (siRNA), a highly attractive tool for selective gene targeting. One of the likely reasons behind the lack of translation is that current in vivo models fail to recapitulate critical elements of clinical solid tumors that may influence drug response, such as cellular heterogeneity in the tumor microenvironment. This study incorporates a more clinically relevant model for assessing siRNA delivery systems; ex vivo culture of prostate cancer harvested from patients who have undergone radical prostatectomy, denoted patient‐derived explants (PDE). The model retains native human tissue architecture, microenvironment, and cell signaling pathways. Porous silicon nanoparticles (pSiNPs) behavior in this model is investigated and compared with commonly used 3D cancer cell spheroids for their efficacy in the delivery of siRNA directed against the androgen receptor (AR), a key driver of prostate cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanowire Synthesis and Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Monash Institute of Pharmaceutical Sciences Monash University Parkville Campus, 381 Royal Parade Parkville Victoria 3052 Australia

CSIRO Manufacturing Bayview Avenue Clayton Victoria 3168 Australia

South Australian Health & Medical Research Institute Adelaide SA 5001 Australia

Adelaide Medical School & Freemasons Foundation Centre for Men's Health University of Adelaide Adelaide SA 5005 Australia

Melbourne Centre for Nanofabrication Victorian Node of the Australian National Fabrication Facility 151 Wellington Road Clayton Victoria 3168 Australia

Funding

Prostate Cancer Foundation of Australia · Movember Foundation · National Health and Medical Research Council

References (62)

Show source-provided references
1. 10.1038/nrd274210.1038/nrd2742 ↗
2. 10.1016/j.copbio.2015.12.01110.1016/j.copbio.2015.12.011 ↗
3. 10.1021/acsnano.7b0473410.1021/acsnano.7b04734 ↗
4. 10.1093/nar/gky123910.1093/nar/gky1239 ↗
5. 10.7150/thno.940410.7150/thno.9404 ↗
6. Luther D. C. · Adv. Drug Delivery Rev. · 2020
7. 10.1002/adtp.20180009510.1002/adtp.201800095 ↗
8. 10.1016/j.omtn.2018.08.00310.1016/j.omtn.2018.08.003 ↗
9. 10.1371/journal.pone.000100610.1371/journal.pone.0001006 ↗
10. 10.1021/acsnano.7b0485510.1021/acsnano.7b04855 ↗
11. 10.1021/acsnano.9b0926310.1021/acsnano.9b09263 ↗
12. 10.1016/j.biomaterials.2020.11979110.1016/j.biomaterials.2020.119791 ↗
13. 10.1038/s41467-019-11718-410.1038/s41467-019-11718-4 ↗
14. 10.1039/C5CS00699F10.1039/C5CS00699F ↗
15. 10.1186/s12967-018-1678-110.1186/s12967-018-1678-1 ↗
16. 10.3389/fbioe.2016.0001210.3389/fbioe.2016.00012 ↗
17. 10.1016/j.biomaterials.2018.05.02410.1016/j.biomaterials.2018.05.024 ↗
18. 10.1021/acs.bioconjchem.9b0013610.1021/acs.bioconjchem.9b00136 ↗
19. 10.1039/C8PY00703A10.1039/C8PY00703A ↗
20. 10.1016/j.pharmthera.2016.03.01310.1016/j.pharmthera.2016.03.013 ↗
21. 10.1371/journal.pone.006263010.1371/journal.pone.0062630 ↗
22. 10.1038/srep1910310.1038/srep19103 ↗
23. 10.1002/mc.2184410.1002/mc.21844 ↗
24. 10.1038/s41416-019-0495-510.1038/s41416-019-0495-5 ↗
25. 10.7554/eLife.5074010.7554/eLife.50740 ↗
26. 10.1016/j.jconrel.2019.07.00610.1016/j.jconrel.2019.07.006 ↗
27. 10.1002/adfm.20190567110.1002/adfm.201905671 ↗
28. 10.1021/acsnano.5b0128810.1021/acsnano.5b01288 ↗
29. 10.1016/j.jconrel.2018.11.02910.1016/j.jconrel.2018.11.029 ↗
30. 10.1038/s41416-019-0682-410.1038/s41416-019-0682-4 ↗
31. 10.1038/nrclinonc.2012.6110.1038/nrclinonc.2012.61 ↗
32. 10.1158/0008-5472.CAN-08-421010.1158/0008-5472.CAN-08-4210 ↗
33. 10.3389/fonc.2018.0001910.3389/fonc.2018.00019 ↗
34. 10.1038/s41598-017-06912-710.1038/s41598-017-06912-7 ↗
35. 10.1158/0008-5472.CAN-13-109310.1158/0008-5472.CAN-13-1093 ↗
36. 10.1002/1878-0261.1235410.1002/1878-0261.12354 ↗
37. 10.1038/nrurol.2013.12610.1038/nrurol.2013.126 ↗
38. 10.1038/s41416-019-0672-610.1038/s41416-019-0672-6 ↗
39. 10.1021/acsami.9b0557710.1021/acsami.9b05577 ↗
40. 10.1101/cshperspect.a03047810.1101/cshperspect.a030478 ↗
41. 10.1158/0008-5472.CAN-17-016410.1158/0008-5472.CAN-17-0164 ↗
42. 10.1021/acs.molpharmaceut.8b0107810.1021/acs.molpharmaceut.8b01078 ↗
43. 10.1039/C4BM00323C10.1039/C4BM00323C ↗
44. 10.1038/s41598-018-35216-710.1038/s41598-018-35216-7 ↗
45. 10.1093/nar/gks88810.1093/nar/gks888 ↗
46. 10.1038/nnano.2010.5810.1038/nnano.2010.58 ↗
47. 10.3390/cells812162010.3390/cells8121620 ↗
48. 10.1007/s10585-019-09966-110.1007/s10585-019-09966-1 ↗
49. 10.7150/thno.3999510.7150/thno.39995 ↗
50. 10.1016/j.biomaterials.2012.05.00210.1016/j.biomaterials.2012.05.002 ↗
51. 10.1038/srep2587910.1038/srep25879 ↗
52. 10.1038/s41565-019-0597-510.1038/s41565-019-0597-5 ↗
53. 10.1021/acs.nanolett.0c0062010.1021/acs.nanolett.0c00620 ↗
54. 10.1016/j.jconrel.2020.07.00710.1016/j.jconrel.2020.07.007 ↗
55. 10.1073/pnas.091414010710.1073/pnas.0914140107 ↗
56. 10.1021/acsami.6b1002910.1021/acsami.6b10029 ↗
57. 10.1021/acsnano.6b0873110.1021/acsnano.6b08731 ↗
58. 10.1158/1078-0432.CCR-17-381110.1158/1078-0432.CCR-17-3811 ↗
59. 10.1158/1078-0432.CCR-19-183410.1158/1078-0432.CCR-19-1834 ↗
60. 10.1038/s41598-019-51549-310.1038/s41598-019-51549-3 ↗
61. 10.1038/ncomms291210.1038/ncomms2912 ↗
62. 10.1038/nbt.333010.1038/nbt.3330 ↗